Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
27,995,500
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
12,757,094
-
Shares change
-
+282,864
-
Total reported value, excl. options
-
$176,293,302
-
Value change
-
+$3,959,949
-
Number of buys
-
26
-
Number of sells
-
-4
-
Price
-
$13.87
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q3 2016
34 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q3 2016.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12,757,094 shares
of 27,995,500 outstanding shares and own 45.57% of the company stock.
Largest 10 shareholders include Flagship Ventures Management, Inc. (4,806,656 shares), FMR LLC (3,506,155 shares), DEERFIELD MANAGEMENT CO (1,812,778 shares), Redmile Group, LLC (892,782 shares), Aisling Capital LLC (508,565 shares), BAKER BROS. ADVISORS LP (204,465 shares), EVENTIDE ASSET MANAGEMENT, LLC (150,000 shares), JPMORGAN CHASE & CO (136,407 shares), BlackRock Fund Advisors (124,634 shares), and Alyeska Investment Group, L.P. (112,637 shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.